Trastuzumab-DKST has Regulatory Approval in US | 48-Week Survival & Safety of Monotherapy

Trastuzumab-DKST has Regulatory Approval in US | 48-Week Survival & Safety of Monotherapy

Annual-Meeting

1 year
81 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco shares the Trastuzumab-DKST has Regulatory Approval in US | 48-Week Survival & Safety of Monotherapy at Annual Meeting 2018
Up Next Autoplay